Literature DB >> 26314782

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

E Senkus1, S Kyriakides2, S Ohno3, F Penault-Llorca4, P Poortmans5, E Rutgers6, S Zackrisson7, F Cardoso8.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26314782     DOI： 10.1093/annonc/mdv298

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  435 in total

1.  P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.

Authors:  André Filipe Vieira; Maria Rita Dionísio; Madalena Gomes; Jorge F Cameselle-Teijeiro; Manuela Lacerda; Isabel Amendoeira; Fernando Schmitt; Joana Paredes
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer.

Authors:  Annette Lischka; Natalie Doberstein; Sandra Freitag-Wolf; Ayla Koçak; Timo Gemoll; Kerstin Heselmeyer-Haddad; Thomas Ried; Gert Auer; Jens K Habermann
Journal:  Clin Cancer Res       Date:  2020-06-10       Impact factor: 12.531

3.  Significance of a positive sentinel lymph node biopsy in staging for distant metastasis in breast cancer: are current guidelines relevant?

Authors:  Tje Hubbard; C Ives
Journal:  Ann R Coll Surg Engl       Date:  2020-04-24       Impact factor: 1.891

4.  Radiological findings on irradiation-CT in patients with non metastatic breast cancer.

Authors:  Hans J Meyer; Johannes Uhlig; Dominik Schramm; Andreas G Bach; Alexey Surov
Journal:  Br J Radiol       Date:  2017-06-16       Impact factor: 3.039

5.  Role of sentinel node in differentiated thyroid cancer: a prospective study comparing patent blue injection technique, lymphoscintigraphy and the combined technique.

Authors:  R Gelmini; M Campanelli; F Cabry; A Franceschetto; G Ceresini; L Ruffini; A Zaccaroni; P Del Rio
Journal:  J Endocrinol Invest       Date:  2017-08-31       Impact factor: 4.256

6.  Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer.

Authors:  Jorge Gomez-Miragaya; Eva González-Suárez
Journal:  Mol Cell Oncol       Date:  2017-06-28

7.  Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.

Authors:  Kelsey H Natsuhara; Katya Losk; Tari A King; Nancy U Lin; Kristen Camuso; Mehra Golshan; Stephen Pochebit; Jane E Brock; Craig A Bunnell; Rachel A Freedman
Journal:  Oncologist       Date:  2018-08-03

Review 8.  Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women.

Authors:  Lorenzo Rossi; Olivia Pagani
Journal:  Curr Treat Options Oncol       Date:  2017-05

9.  Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?

Authors:  Lucía Graña-López; Michel Herranz; Inés Domínguez-Prado; Sonia Argibay; Ángeles Villares; Manuel Vázquez-Caruncho
Journal:  Eur Radiol       Date:  2019-08-02       Impact factor: 5.315

Review 10.  The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis.

Authors:  M Luke Marinovich; Lamiae Azizi; Petra Macaskill; Les Irwig; Monica Morrow; Lawrence J Solin; Nehmat Houssami
Journal:  Ann Surg Oncol       Date:  2016-08-15       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.